State of the art

Alliance of leading expert scientists in both academic and industrial worlds, GEN2X LLC. provide contract and development services for biotechnology and pharmaceutical companies. We specialize in X-ray protein crystallography.

Affordable

Our goal is to provide you with the 3D structure of the protein essential to your business model and to help you bring it to the level of structure based drug design in an affordable way.

SBDD versus HTS: improve hits quality

Successful High-Throughput Screening (HTS) of compound libraries depends on a number of factors including a convenient HT activity or binding assay for the target, and stable compounds.

On the other hand, structure-based drug design uses the known three- dimensional structure of a target protein interacting with a small molecule in the active site as the primary source of information, allowing you to decrease cost and increase productivity.

Moreover, while computer-assisted drug research is a recent development for the de novo design of protein ligands, structure-based design can be regarded as the predominant strategy during the last decade.

Better pharmacological chemical properties more quickly

Combinatorial chemistry coupled to structure-based drug design is a very powerful tool for lead optimization: in the situation where HTS of a compound library yields interesting hits, the crystal structure of the drug target in complex with the potential drug candidate can help you to rationally alter the compound in order to increase it's drug like qualities.